Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix booster immunogenicity in preterm versus term children at 4 years
2004-001223-37Phase 4
- Sponsor
- GSK
- Start
- Sep 2004
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of acellular pertussis vaccine in diphtheria, Tetanus and pertussis (2 arms), sponsored by GSK. Primary endpoints: Geometric mean antibody concentrations against pertussis antigens and Non-inferiority of immunogenicity in preterm versus term children.
02
Drugs
acellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on 2004-001223-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001223-37.